Procalcitonin in Hepatocellular Carcinoma

Ain Shams University

Status: Completed

Conditions: Hepatocellular Carcinoma

Study type: Observational

Funder types: Other

Identifiers

NCT01518829

HCC and Procalcitonin

Details and patient eligibility

About

the value of serum procalcitonin in differentiation between bacterial infection and non infectious inflammation in febrile HCC patients following locoeregional treatment for HCC.

Enrollment: 42 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. • Hepatocellular carcinoma patients who will undergo TACE and/or radio-frequency.
2. • Fever more than 38C after 48 hours post intervention.

Exclusion criteria

1. HCC Patients who does not develop fever after intervention.
2. Proven infection elsewhere (e.g. UTI, chest infection..)

Trial design

42 participants in 2 patient groups

Patients with hepatocellular carcinoma

Description:

Patients with hepatocellular carcinoma who will undergo locoregional therapy

patients with chronic liver disease

Description:

patients with chronic liver disease, as a control group